Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Case report of rhabdomyosarcomatous transformation of a primary gastrointestinal stromal tumor (GIST).

Li L, Khalili M, Johannes G, Baratam P, Morano WF, Styler M, Bowne WB, Hou JS.

BMC Cancer. 2019 Sep 13;19(1):913. doi: 10.1186/s12885-019-6085-3.

2.

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.

Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.

Am J Surg Pathol. 2009 Feb;33(2):218-26. doi: 10.1097/PAS.0b013e31817ec2e6.

PMID:
18830121
3.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
4.

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.

Boichuk S, Galembikova A, Dunaev P, Valeeva E, Shagimardanova E, Gusev O, Khaiboullina S.

Molecules. 2017 Dec 5;22(12). pii: E2152. doi: 10.3390/molecules22122152.

5.

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.

Zheng S, Huang KE, Pan YL, Zhou Y, Pan SD, Li X, Jia J, Zheng XL, Tao DY.

Gastric Cancer. 2015 Oct;18(4):796-802. doi: 10.1007/s10120-014-0414-7. Epub 2014 Aug 15.

PMID:
25182956
6.

Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.

Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos PA, Fletcher CD.

Am J Surg Pathol. 2013 Mar;37(3):385-92. doi: 10.1097/PAS.0b013e31826c1761.

7.

[The importance of mutational status in prognosis and therapy of GIST].

Comandone A, Boglione A.

Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Italian.

PMID:
25621775
8.

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD.

Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Review.

PMID:
11740803
9.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052
11.

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D.

Oncogene. 2007 Jun 7;26(27):3909-19. Epub 2007 Feb 26.

PMID:
17325667
12.

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.

Na YS, Ryu MH, Yoo C, Lee JK, Park JM, Lee CW, Lee SY, Shin YK, Ku JL, Ahn SM, Kang YK.

Oncotarget. 2017 Sep 11;8(44):76712-76721. doi: 10.18632/oncotarget.20816. eCollection 2017 Sep 29.

13.

Management of rectal gastrointestinal stromal tumor.

Kameyama H, Kanda T, Tajima Y, Shimada Y, Ichikawa H, Hanyu T, Ishikawa T, Wakai T.

Transl Gastroenterol Hepatol. 2018 Feb 1;3:8. doi: 10.21037/tgh.2018.01.08. eCollection 2018. Review.

14.

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.

Jiang X, Anderson HB, Guy CD, Mosca PJ, Riedel RF, Cardona DM.

Case Rep Oncol Med. 2015;2015:317493. doi: 10.1155/2015/317493. Epub 2015 Jan 28.

15.

Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.

Jung M, Park SH, Jeon YK, Won JK, Yang HK, Kim WH.

Medicine (Baltimore). 2017 Dec;96(49):e9031. doi: 10.1097/MD.0000000000009031.

16.
17.

[The diagnostic and predictive role of kit (CD117)].

Dirnhofer S, Zimpfer A, Went P.

Ther Umsch. 2006 Apr;63(4):273-8. German.

PMID:
16689459
18.

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.

Nishida T, Doi T, Naito Y.

Expert Opin Pharmacother. 2014 Oct;15(14):1979-89. doi: 10.1517/14656566.2014.937707. Epub 2014 Jul 3. Review.

PMID:
24990162
19.

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.

Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K.

Cancer Biol Ther. 2005 Nov;4(11):1270-4. Epub 2005 Nov 18.

PMID:
16294026
20.

Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.

Miettinen M, Majidi M, Lasota J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51. Review.

PMID:
12528772

Supplemental Content

Support Center